carbamates has been researched along with plx4032 in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Belum, VR; Busam, KJ; Carvajal, RD; Chapman, PB; Dranitsaris, G; Jaimes, N; Lacouture, ME; Marghoob, AA; Pulitzer, MP; Rosen, AC | 1 |
| Adelmann, CH; Bansal, V; Ching, G; Du, L; Lee, W; Liang, R; Pence, LJ; Saporito, RC; Tsai, KY | 1 |
| Aractingi, S; Avril, MF; Boitier, F; Boulinguez, S; Chanal, J; Deilhes, F; Dupin, N; Guégan, S; Kramkimel, N; Meyer, N; Regnier-Rosencher, E; Vanhaecke, C | 1 |
| Avan, A; Bahrami, A; Ferns, GA; Hassanian, SM; Hesari, A; Khazaei, M | 1 |
| Daud, A; Tsai, K | 1 |
| Alaibac, M; Chiarion Sileni, V; Frigo, AC; Russo, I; Zorzetto, L | 1 |
| Dippel, E; Gutzmer, R; Herbst, R; Kreuter, A; Mohr, P; Okoye, S; Pföhler, C; Satzger, I; Schadendorf, D; Schaper-Gerhardt, K; Sucker, A; Terheyden, P; Ugurel, S; Ulrich, J; Utikal, JS | 1 |
| Grob, JJ | 1 |
| Arance, A; Ascierto, PA; Chiarion-Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N | 1 |
| Sidaway, P | 1 |
| Martin-Liberal, J | 1 |
| Arance, A; Ascierto, PA; Chiarion Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N | 1 |
| Aebersold, R; Bileck, A; Chatziisaak, TP; Cheng, PF; Dummer, R; Eichhoff, O; Freiberger, SN; Gerner, C; Guenova, E; Irmisch, A; Knapp, B; Kunstfeld, R; Leitner, A; Levesque, MP; Mangana, J; Mohr, T; Paulitschke, P; Paulitschke, V; Pehamberger, H; Saulite, I; Stephan, J; Zila, N | 1 |
| Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D; Sileni, VC; Yamazaki, N | 1 |
| Assi, T; Farhat, F; Kattan, C; Kattan, J | 1 |
| Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D | 1 |
| Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H | 1 |
| Calapre, L; Gray, ES; McEvoy, A; Meniawy, TM; Millward, M; Pereira, M; Warburton, L; Ziman, M | 1 |
| Enzler, F; Feichtner, A; Fleischmann, J; Hartl, M; Huber, RG; Mayrhofer, JE; Ogris, E; Raffeiner, A; Röck, R; Schneider, R; Stefan, E; Torres-Quesada, O; Troppmair, J; Tschaikner, P | 1 |
| Baric, L; Cantagrel, A; Di Palma, M; Ederhy, S; Paques, M; Perlemuter, G; Sibaud, V | 1 |
| Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH | 1 |
| Arance, A; Ascierto, PA; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, H; Gollerkeri, A; Gutzmer, R; Jan de Willem, G; Krajsová, I; Liszkay, G; Loquai, C; Mandalà, M; Murris, J; Queirolo, P; Robert, C; Schadendorf, D; Sellier, AT; Sileni, VC; Suissa, J; Yamazaki, N | 1 |
| Berardi, R; Corrie, P; Guidoboni, M; Kolovos, S; Laramée, P; Macabeo, B; Meyer, N; Schlueter, M; Trouiller, JB | 1 |
4 review(s) available for carbamates and plx4032
| Article | Year |
|---|---|
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cinnamates; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Oximes; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2018 |
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Fever; Humans; Imidazoles; Indoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Sulfonamides; Vemurafenib | 2017 |
[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Drug Combinations; Humans; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Vemurafenib | 2021 |
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Network Meta-Analysis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2022 |
5 trial(s) available for carbamates and plx4032
| Article | Year |
|---|---|
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult | 2018 |
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Disease Progression; Female; Genetic Predisposition to Disease; Humans; Male; Melanoma; Middle Aged; Mutation; Phenotype; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult | 2018 |
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Fatigue; Female; Humans; Incidence; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Nausea; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting | 2019 |
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Diarrhea; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Nausea; Outcome Assessment, Health Care; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting | 2020 |
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Quality of Life; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult | 2021 |
14 other study(ies) available for carbamates and plx4032
| Article | Year |
|---|---|
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Female; Humans; Imidazoles; Indoles; Male; Middle Aged; Neoplasms; Oximes; Protein Kinase Inhibitors; Skin Diseases; Sulfonamides; Vemurafenib | 2015 |
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
Topics: Apoptosis; Carbamates; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Enzyme Activation; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2016 |
BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Topics: Adult; Antineoplastic Agents; Carbamates; Drug Substitution; Humans; Imidazoles; Indoles; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Oximes; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult | 2017 |
A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Melanoma; Melanoma, Cutaneous Malignant; Mutation; Oximes; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Skin Neoplasms; Sulfonamides; Vemurafenib | 2017 |
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carbamates; Female; Humans; Imidazoles; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Oximes; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult | 2018 |
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma?
Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2018 |
Encorafenib - a new agent for advanced-stage disease.
Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2018 |
Encorafenib plus binimetinib: an embarrassment of riches.
Topics: Benzimidazoles; Carbamates; Embarrassment; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2018 |
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Topics: Adult; Aged; Carbamates; Cell Adhesion; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Melanoma; Middle Aged; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; RNA-Binding Proteins; Sequence Analysis, RNA; Sulfonamides; Survival Analysis; Up-Regulation; Vemurafenib | 2019 |
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resistance, Neoplasm; Humans; Lymph Node Excision; Male; MAP Kinase Kinase 1; Margins of Excision; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2019 |
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib | 2020 |
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma.
Topics: Adult; Aged; Carbamates; Circulating Tumor DNA; Disease Progression; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2020 |
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
Topics: A549 Cells; Carbamates; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Lung Neoplasms; Mutation; Oximes; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2020 |
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Cardiovascular Diseases; Colonic Neoplasms; Cross-Sectional Studies; Female; Heart Failure; Humans; Hypertension; Imidazoles; Lung Neoplasms; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Registries; Regression Analysis; Skin Neoplasms; Sulfonamides; Vemurafenib; Venous Thromboembolism; Young Adult | 2021 |